AbbVie clinical trial pipeline

47 trials changed in the last 30 days: 1 stopped, 15 with notable changes, 31 with minor changes only.

1. Stopped

   LIVEN · Change in Disease State · Acute Myeloid Leukemia (AML)…LIVEN · Change in Disease State · Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

   Trial terminated

   Also in this update: Primary completion date changed from estimate of Mar 2027 to Aug 31, 2026

   AbbVie·Not specified· NCT05424562· Registry history of NCT05424562 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

2. Notable

   U-EMPOWER · Crohn's Disease: Efficacy, Safety, and…U-EMPOWER · Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib · Moderately to Severely Active Crohn's Disease

   Primary completion pushed from Jun 2027 to Jan 2031

   Also in this update: Enrollment closed, study ongoing; Study completion moved earlier from Dec 2034 to Jan 2031

   AbbVie·Phase 3· NCT06332534· Registry history of NCT06332534 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

3. Notable

   How the Study Drug Moves Through the Body, Adverse Events, and How…How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

   Primary and study completion pushed from Aug 2027 to May 2028

   Also in this update: Enrollment increased: 121 → 142 participants; Trial sites reduced: 23 → 20 locations

   AbbVie·Phase 1· NCT07232004· Registry history of NCT07232004 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

4. Notable

   Adverse Events, Change in Disease Activity of Intravenous…Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment · Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

   Primary completion pushed from Dec 2031 to Nov 2036

   Also in this update: Trial sites expanded: 53 → 65 locations

   AbbVie·Phase 2/3· NCT07005102· Registry history of NCT07005102 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

5. Notable

   Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult…Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

   Primary and study completion pushed from Sep 2027 to Jun 2028

   AbbVie·Not specified· NCT06916507· Registry history of NCT06916507 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

6. Notable

   Change in Disease Activity and Adverse Events (AE)s · Multiple…Change in Disease Activity and Adverse Events (AE)s · Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

   Primary endpoint(s) modified

   Also in this update: Interventions modified; Study completion pushed from Dec 2035 to Mar 2036

   AbbVie·Phase 1/2· NCT06892522· Registry history of NCT06892522 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

7. Notable

   Different Targeted Therapies · Rheumatoid Arthritis

   Primary endpoint(s) modified

   Also in this update: Interventions modified; Trial arms changed: 12 → 6; and 4 more changes in the last 30 days

   AbbVie·Phase 2· NCT06972446· Registry history of NCT06972446 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

8. Notable

   Adverse Events, Change in Disease Activity and How Intravenous…Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs · Ovarian Cancer

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 219 → 285 participants; Trial sites expanded: 17 → 22 locations; and 1 more change in the last 30 days

   AbbVie·Phase 1· NCT07278336· Registry history of NCT07278336 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

9. Notable

   Adverse Events and Disease Activity of Intravenously (IV) Infused…Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan · c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

   Phase changed: Phase 3 → Phase 2

   AbbVie·Phase 2· NCT06614192· Registry history of NCT06614192 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

10. Notable

    Adverse Events, Change in Disease Activity and How Intravenous…Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body · Advanced Solid Tumors

    Recruitment opened

    Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Sep 1, 2026 to Sep 14, 2026

    AbbVie·Phase 1· NCT07807956· Registry history of NCT07807956 on ClinicalTrials.gov (opens the registry)

    Oct 16, 2026

11. Notable

    AURA · Participant Satisfaction After Jawline and Neck Treatment

    Recruitment opened

    Also in this update: Start date changed from estimate of Sep 4, 2026 to Sep 9, 2026

    AbbVie·Phase 4· NCT07794891· Registry history of NCT07794891 on ClinicalTrials.gov (opens the registry)

    Oct 8, 2026

12. Notable

    Adverse Events, Change in Disease Activity and Optimal Dose of…Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruitment opened

    Also in this update: Trial sites expanded: 0 → 3 locations

    AbbVie·Phase 2· NCT07744126· Registry history of NCT07744126 on ClinicalTrials.gov (opens the registry)

    Sep 29, 2026

13. Notable

    Adverse Events and Change in Disease Activity With Treatment…Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults · Pancreatobiliary Cancers

    Recruitment opened

    Also in this update: Primary and study completion moved earlier from Nov 2028 to Sep 2028

    AbbVie·Phase 2· NCT07769502· Registry history of NCT07769502 on ClinicalTrials.gov (opens the registry)

    Sep 22, 2026

14. Notable

    Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of…Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Primary completion moved earlier from Apr 2031 to Mar 2030

    AbbVie·Phase 3· NCT07821684· Registry history of NCT07821684 on ClinicalTrials.gov (opens the registry)

    Oct 5, 2026

15. Notable

    Change in Disease Activity and Adverse Events of Intravenous…Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) · Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Primary completion moved earlier from Jan 2042 to Sep 2040

    Also in this update: Interventions modified; Study completion moved earlier from Jan 2042 to May 2041; and 2 more changes in the last 30 days

    AbbVie·Phase 2/3· NCT07095452· Registry history of NCT07095452 on ClinicalTrials.gov (opens the registry)

    Sep 22, 2026

16. Notable

    LIVIGNO-2 · Adverse Events, and Change in Disease Activity of…LIVIGNO-2 · Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution · Hepatocellular Carcinoma (HCC)

    Primary and study completion moved earlier from Sep 2030 to Jan 2027

    Also in this update: Enrollment closed, study ongoing; Final enrollment: 89 participants (planned 660)

    AbbVie·Phase 2/3· NCT06109272· Registry history of NCT06109272 on ClinicalTrials.gov (opens the registry)

    Sep 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.